

Supplementary Online Materials

Industry Funding Independent Variable (IV) Type.	
Stratified	Study provides a quantitative assessment of the relationship between different types of industry funding and one or more outcomes of interest. Industry funding may be analyzed as a categorical variable or as a series of dichotomous variables representing a range of industry funding categories. Funder stratifications may include level of involvement (primary, secondary), relationship to drug or device under study (manufacturer, competitor), or mode of sponsorship (study sponsor, medication provider, author employer).
Unstratified	Industry funding is analyzed as a dichotomous variable or as one category in a categorical variable, e.g. funder types might include industry, government, nonprofit.
Magnitude	Industry funding is a continuous variable representing either the total number of industry funders per study or total dollar value of contributions.
Author COI IV Type	
Stratified	Study provides a quantitative assessment of the relationship between different types of COI and one or more outcomes of interest. Industry funding may be analyzed as a categorical variable or as a series of dichotomous variables representing a range of COI categories. COI stratifications may include type of disbursement (employment, speaker fees, etc) and affiliation (trial sponsor vs. non-sponsor funder).
Unstratified	COI is analyzed as a dichotomous variable or as one category in a categorical variable, e.g., Industry funding, Author COI, Government Funding.
Magnitude	COI is a continuous variable representing either the total number of relationships or the total dollar value of contributions.
COI as Proxy for Industry Funding Study	
Yes	Disclosed author COI are used as inclusion criteria for industry funding.
No	Disclosed COI are not used as inclusion criteria for industry funding or industry funding is not measured.
IV Dichotomization	
NA	The IV used in the statistical analysis was stratified or an assessment of magnitude.
Yes	The categorical schema was converted to dichotomous variables that were used for analysis.
No	The IV was consistently treated as dichotomous throughout the article.
Dependent Variable Type (DV Type)	
Outcome	The analysis evaluates if chosen IVs are associated with results indicating the success of the intervention (drug, device, etc) or are otherwise favorable to trial sponsors. Includes drug efficacy, response rate, positive interpretation of findings, etc.
Safety	The analysis evaluates if chosen IVs associate with results related to drug safety.
Quality	The analysis evaluates if chosen IVs are associated with results related to methodological or reporting quality. Includes issues of statistical power, risk of bias, presence of hype or spin.
Reporting	The analysis evaluates whether or not trial results were reported at all. May include reporting to ClinicalTrials.gov or publication of findings.

Supplemental Table 1. Methodological Design Feature Schema for Analyzed Studies. Definition and details for industry funding IV type, author COI IV type, COI as proxy for industry funding, dichotomization, and DV type analyses.

<i>Article</i>	<i>Year</i>	<i>IF IV Type</i>	<i>COI IV Type</i>	<i>DV Type</i>	<i>COI Proxy</i>	<i>IF Dichotomize</i>	<i>COI Dichotomize</i>
<i>Abildgaard et al. (1)</i>	2019	Unstratified	None	Outcome	yes	yes	NA
<i>Addeo et al. (2)</i>	2019	Unstratified	None	Outcome, Safety	no	no	NA
<i>Abmer et al. (3)</i>	2005	Stratified	Unstratified	Outcome	no	NA	no
<i>Abn et al. (4)</i>	2016	Unstratified	Unstratified	Outcome	no	no	yes
<i>Alasbali et al. (5)</i>	2009	Unstratified	None	Outcome, Quality	no	no	NA
<i>Als-Nielsen et al. (6)</i>	2003	Unstratified	None	Outcome	yes	NA	NA
<i>Avni et al. (7)</i>	2004	Unstratified	None	Quality	no	no	NA
<i>Azad et al. (8)</i>	2019	Unstratified	None	Quality	no	NA	NA
<i>Azharuddin et al. (9)</i>	2020	Unstratified	None	Quality	no	no	NA
<i>Barden et al. (10)</i>	2005	Unstratified	None	Outcome	yes	no	NA
<i>Bariani et al. (11)</i>	2013	Unstratified	Unstratified	Outcome	no	yes	yes
<i>Bartels et al. (12)</i>	2012	Unstratified	Stratified	Outcome	yes	no	NA
<i>Bero et al. (13)</i>	2007	Unstratified	Unstratified	Outcome	no	NA	no
<i>Bhandari et al. (14)</i>	2004	Unstratified	None	Outcome	no	yes	no
<i>Bigbelli et al. (15)</i>	2020	Unstratified	Unstratified	Quality	no	no	NA
<i>Bond et al. (16)</i>	2012	Stratified	Unstratified	Outcome	yes	NA	no
<i>Booth et al. (17)</i>	2008	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Bourgeois et al. (18)</i>	2010	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Brown et al. (19)</i>	2006	Unstratified	None	Outcome, Quality	no	no	NA
<i>Buchkowsky and Jewesson (20)</i>	2004	Unstratified	Unstratified	Outcome	no	NA	no
<i>Budhiraja et al. (21)</i>	2021	Unstratified	None	Outcome	no	NA	NA
<i>Bugano et al et al. (22)</i>	2017	Unstratified	None	Outcome, Quality	no	no	NA
<i>Catillon (23)</i>	2019	Unstratified	Unstratified	Quality	no	no	NA
<i>Chang et al. (24)</i>	2021	Unstratified	None	Quality	no	NA	NA
<i>Chard et al. (25)</i>	2000	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Chen et al. (26)</i>	2016	Unstratified	None	Reporting	no	NA	NA
<i>Cherla et al. (27)</i>	2018	None	Stratified	Outcome	no	NA	NA
<i>Cho and Bera (28)</i>	1996	Unstratified	None	Outcome, Quality	yes	no	NA
<i>Clark et al. (29)</i>	2002	Unstratified	None	Outcome	no	no	NA
<i>Clifford et al. (30)</i>	2002	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Corona et al. (31)</i>	2014a	Unstratified	None	Quality, Safety	yes	no	NA
<i>Corona et al. (32)</i>	2014b	Unstratified	None	Outcome, Quality	yes	no	NA
<i>Cristea et al. (33)</i>	2017	None	Unstratified	Outcome	no	NA	no
<i>Crocetti et al. (34)</i>	2010	Unstratified	None	Quality	no	NA	NA
<i>Davidović et al. (35)</i>	2021	Unstratified	None	Outcome, Reporting	no	no	NA
<i>Davidson (36)</i>	1986	Unstratified	None	Outcome	yes	no	NA

Supporting Information, p. 2

<i>Davis et al. (37)</i>	2008	Unstratified	None	Outcome	yes	no	NA
<i>de Souza Gutierrez et al. (38)</i>	2020	Unstratified	None	Quality	no	no	NA
<i>DeFrance et al. (39)</i>	2021	None	Unstratified	Outcome	no	NA	no
<i>DeGeorge et al. (40)</i>	2015	Unstratified	Unstratified	Outcome	no	NA	no
<i>Del Paggio et al. (41)</i>	2017	Unstratified	None	Outcome, Quality	no	no	NA
<i>Falk Delgado and Falk Delgado (42)</i>	2017a	Unstratified	None	Outcome	no	NA	NA
<i>Falk Delgado and Falk Delgado (43)</i>	2017b	Unstratified	Unstratified	Reporting	no	NA	no
<i>DePasse et al. (44)</i>	2018	Unstratified	None	Reporting	no	NA	NA
<i>DeVito et al. (45)</i>	2020	Unstratified	None	Reporting	no	NA	NA
<i>Djulfbegovic et al. (46)</i>	2013	Unstratified	None	Outcome	no	no	NA
<i>Djulfbegovic et al. (47)</i>	2000	Unstratified	None	Quality	yes	no	NA
<i>Etter et al. (48)</i>	2007	Unstratified	None	Outcome	yes	no	NA
<i>Finucane and Boulton (49)</i>	2004	Unstratified	None	Outcome	yes	no	NA
<i>Flacco et al. (50)</i>	2015	Unstratified	Unstratified	Outcome, Quality	yes	yes	no
<i>Fraguas et al. (51)</i>	2018	Unstratified	None	Quality	no	no	NA
<i>Freemantle et al. (52)</i>	2000	Unstratified	None	Outcome	no	no	NA
<i>Fung et al. (53)</i>	2017	Unstratified	None	Quality, Reporting	no	no	NA
<i>Gabler et al. (54)</i>	2016	Unstratified	None	Reporting, Quality	no	no	NA
<i>Gan et al. (55)</i>	2012	Unstratified	None	Quality	no	no	NA
<i>Gao et al. (56)</i>	2019	Unstratified	None	Quality	no	NA	NA
<i>Gartlehner et al. (57)</i>	2010	Unstratified	None	Outcome, Quality	yes	no	NA
<i>Gandino et al. (58)</i>	2020	Unstratified	Unstratified	Outcome, Quality	yes	no	yes
<i>Gonzalez et al. (59)</i>	2019	Unstratified	None	Quality	no	NA	NA
<i>Grey et al. (60)</i>	2018	Unstratified	None	Outcome	no	no	NA
<i>Gyawali et al. (61)</i>	2019	Unstratified	None	Safety	no	NA	NA
<i>Hajibandeh et al. (62)</i>	2017	Unstratified	Unstratified	Outcome	no	no	no
<i>Halpern et al. (63)</i>	2004	Unstratified	None	Quality	no	NA	NA
<i>Hanna et al. (64)</i>	2016	Unstratified	None	Outcome	no	NA	NA
<i>Hasbemiour et al. (65)</i>	2019	Unstratified	Unstratified	Outcome	no	no	no
<i>Hengartner et al. (66)</i>	2021	Unstratified	None	Safety	yes	no	NA
<i>Heres et al. (67)</i>	2006	Unstratified	None	Outcome	no	no	NA
<i>Janiand et al. (68)</i>	2018	Unstratified	None	Outcome	no	yes	NA
<i>Jefferson et al. (69)</i>	2009	Unstratified	None	Quality	no	no	NA
<i>Jellison et al. (70)</i>	2020	Unstratified	None	Quality	no	yes	NA
<i>Jinapriya et al. (71)</i>	2011	Stratified	None	Outcome	no	NA	NA
<i>Johnson et al. (72)</i>	2020	Unstratified	None	Reporting	no	NA	NA

<i>Jones et al. (73)</i>	2010	Unstratified	None	Quality	no	NA	NA
<i>Kakkar et al. (74)</i>	2019	Unstratified	None	Quality	no	no	NA
<i>Kapeliou et al. (75)</i>	2020	Unstratified	None	Outcome, Quality	no	no	NA
<i>Kelly et al. (76)</i>	2006	Stratified	None	Outcome	yes	NA	NA
<i>Kemmeren et al. (77)</i>	2001	Unstratified	None	Safety	no	no	NA
<i>Khan et al. (78)</i>	2012	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Killin et al. (79)</i>	2014	Unstratified	None	Outcome	yes	no	NA
<i>Kjaergard and Als-Nielsen (80)</i>	2002	Unstratified	None	Outcome	no	NA	NA
<i>Lee et al. (81)</i>	2012	Unstratified	None	COI, Outcome	no	no	NA
<i>Lee et al. (82)</i>	2020	Unstratified	None	Reporting	no	no	NA
<i>Leite et al. (83)</i>	2017	Unstratified	Unstratified	Outcome	no	no	no
<i>Leucht et al. (84)</i>	2017	Unstratified	None	Outcome, Quality	no	no	NA
<i>Leucht et al. (85)</i>	2019	Unstratified	None	Outcome	no	no	NA
<i>Linker et al. (86)</i>	2017	Unstratified	None	Outcome, Quality	no	NA	NA
<i>Liss (87)</i>	2006	Unstratified	None	Outcome	yes	no	NA
<i>Liu et al. (88)</i>	2018	Unstratified	None	Outcome	no	NA	NA
<i>Lubowitz et al. (89)</i>	2007	Unstratified	None	Outcome	no	no	NA
<i>Lynch et al. (90)</i>	2007	Unstratified	None	Outcome, Quality	yes	NA	NA
<i>Ma et al. (91)</i>	2014	Unstratified	None	Outcome, Safety	no	no	NA
<i>Magnani et al. (92)</i>	2021	Unstratified	None	Reporting, Outcome	no	NA	NA
<i>Maillet et al. (93)</i>	2015	Unstratified	None	Outcome	no	no	NA
<i>Malek et al. (94)</i>	2017	Unstratified	None	Outcome	no	no	NA
<i>Mian et al. (95)</i>	2020	Unstratified	None	Quality	no	NA	NA
<i>Mitchell and Patterson (96)</i>	2020	Unstratified	None	Quality	no	NA	NA
<i>Momeni et al. (97)</i>	2009	Unstratified	None	Outcome	no	NA	NA
<i>Moncrieff (98)</i>	2003	Unstratified	None	Outcome	no	no	NA
<i>Montgomery et al. (99)</i>	2004	Unstratified	Unstratified	Outcome, Quality	no	no	no
<i>Moraes et al. (100)</i>	2017	Unstratified	Unstratified	Outcome	no	NA	no
<i>Mossman et al. (101)</i>	2021	Unstratified	None	Outcome	no	no	NA
<i>Naci et al. (102)</i>	2014	Unstratified	None	Outcome, Quality	no	no	NA
<i>Ng et al. (103)</i>	2016	Unstratified	None	Quality	no	no	NA
<i>Nieto et al. (104)</i>	2007	Unstratified	None	Safety	no	no	NA
<i>Nithianandan et al. (105)</i>	2020	Unstratified	Unstratified	Outcome	no	no	no
<i>Odutayo et al. (106)</i>	2017	Unstratified	None	Outcome	no	no	NA
<i>Paggio et al. (107)</i>	2021	Unstratified	None	Quality	no	no	NA
<i>Pasalic et al. (108)</i>	2020	Unstratified	None	Quality	no	no	NA
<i>Pengel et al. (109)</i>	2009	Unstratified	None	Quality	yes	NA	NA

Supporting Information, p. 4

<i>Pepper et al. (110)</i>	2019	Unstratified	None	Safety	no	no	NA
<i>Peppercorn et al. (111)</i>	2007	Unstratified	Unstratified	Outcome	yes	no	no
<i>Perlis et al. (112)</i>	2005a	Unstratified	Unstratified	Outcome, Quality	yes	no	no
<i>Perlis et al. (113)</i>	2005b	Unstratified	Unstratified	Outcome	yes	no	no
<i>Popelut et al. (114)</i>	2010	Unstratified	None	Outcome	no	NA	no
<i>Pouwels et al. (115)</i>	2017	Unstratified	None	Outcome, Quality	no	no	NA
<i>Prakash et al. (116)</i>	2018	Unstratified	None	Quality	no	NA	NA
<i>Price-Haywood et al. (117)</i>	2019	Unstratified	None	Safety	no	NA	NA
<i>Printz et al. (118)</i>	2013	Unstratified	None	Outcome	yes	no	NA
<i>Probst et al. (119)</i>	2016	Unstratified	None	Outcome	no	no	NA
<i>Punja et al. (120)</i>	2016	Unstratified	None	Outcome, Safety	no	no	NA
<i>Putman et al. (121)</i>	2021	Unstratified	None	Quality	yes	no	NA
<i>Raman et al. (122)</i>	2018	Unstratified	Unstratified	Outcome	no	NA	no
<i>Rasmussen et al. (123)</i>	2009	Unstratified	None	Outcome	yes	yes	NA
<i>Rattinger and Bero (124)</i>	2009	Stratified	Stratified	Outcome	yes	NA	NA
<i>Reda et al. (125)</i>	2016	Unstratified	None	Outcome, Quality	no	yes	NA
<i>Rees et al. (126)</i>	2019	Unstratified	None	Reporting	no	NA	NA
<i>Ridker and Torres (127)</i>	2006	Unstratified	None	Outcome	no	NA	NA
<i>Rios et al. (128)</i>	2008	Unstratified	None	Quality	no	NA	NA
<i>Rochon et al. (129)</i>	1994	Unstratified	None	Outcome, Quality	yes	no	NA
<i>Roddick et al. (130)</i>	2017	Unstratified	None	Outcome	no	NA	NA
<i>Røper et al. (131)</i>	2014	Unstratified	None	Limitations, Outcome	no	NA	NA
<i>Rosner et al. (132)</i>	2010	Unstratified	None	Outcome, Quality	no	no	NA
<i>Rosner et al. (133)</i>	2011	Unstratified	None	Outcome	no	NA	no
<i>Saa et al. (134)</i>	2018	Stratified	None	Outcome, Quality	yes	NA	NA
<i>Saleh et al. (135)</i>	2020	Unstratified	None	Outcome	no	no	NA
<i>Sendyk et al. (136)</i>	2019	Unstratified	None	Quality, Reporting	no	no	NA
<i>Shepard et al. (137)</i>	2021	Unstratified	None	Quality	no	NA	NA
<i>Silva et al. (138)</i>	2017	Unstratified	None	Safety, Quality	no	no	NA
<i>Simonetti et al. (139)</i>	2019	Unstratified	None	Safety	no	no	NA
<i>Sinyor et al. (140)</i>	2012	Unstratified	None	Outcome, Safety	yes	no	NA
<i>Son et al. (141)</i>	2016	Unstratified	None	Outcome	no	no	NA
<i>Spanenberg et al. (142)</i>	2011	Unstratified	None	Outcome, Quality	no	no	NA
<i>Sriganesh et al. (143)</i>	2017	Unstratified	None	Quality	no	no	NA
<i>Stefuniak et al. (144)</i>	2017	Unstratified	None	Reporting, Quality	no	NA	NA
<i>Steffens et al. (145)</i>	2021	Unstratified	None	Quality	yes	no	NA

Supporting Information, p. 5

<i>Sung et al. (146)</i>	2013	Unstratified	None	Outcome	yes	no	NA
<i>Tiabau et al. (147)</i>	2018	Unstratified	None	Outcome	no	NA	NA
<i>Trinquart et al. (148)</i>	2018	Unstratified	None	Reporting	no	no	NA
<i>Tulukangas et al. (149)</i>	2006	Unstratified	None	Outcome	no	no	NA
<i>Tungaraza and Poole (150)</i>	2007	Unstratified	Unstratified	Outcome	no	no	no
<i>Urrutia et al. (151)</i>	2016	Unstratified	None	Reporting	no	no	NA
<i>van den Bogert et al. (152)</i>	2017	Unstratified	None	Quality	no	yes	NA
<i>van Heteren et al. (153)</i>	2019	Unstratified	None	Reporting	no	NA	NA
<i>Van Lent et al. (154)</i>	2014	Unstratified	None	Outcome	yes	NA	NA
<i>Venincasa et al. (155)</i>	2019	Unstratified	Unstratified	Outcome	no	no	no
<i>Vlad et al. (156)</i>	2007	Stratified	Unstratified	Outcome, Quality	no	NA	no
<i>Walkup et al. (157)</i>	2017	Unstratified	None	Outcome	no	no	NA
<i>Walter et al. (158)</i>	2020	Unstratified	None	Reporting	no	no	NA
<i>Waqas et al. (159)</i>	2019	Unstratified	Unstratified	Outcome	no	no	no
<i>Welsb et al. (160)</i>	2018	Unstratified	Unstratified	Reporting	no	NA	no
<i>Wise et al. (161)</i>	2021	Unstratified	Unstratified	Outcome	no	yes	yes
<i>Wong et al. (162)</i>	2019	Unstratified	None	Outcome	no	no	NA
<i>Wortzel et al. (163)</i>	2020	Unstratified	None	Quality	no	NA	NA
<i>Xu et al. (164)</i>	2013	Unstratified	None	Safety	no	no	NA
<i>Yilmaz et al. (165)</i>	2018	Unstratified	None	Reporting	no	no	NA
<i>Youssef et al. (166)</i>	2016	Unstratified	None	Outcome	no	no	NA
<i>Zhang et al. (167)</i>	2013	Unstratified	None	Outcome, Safety	no	no	NA

Supplemental Table 2. Methodological Design Analysis for All Collected Articles. Includes industry funding IV type, author COI IV type, DV type(s), COI as proxy, and dichotomization data.

Supplemental References

1. Abildgaard JT, Chung AS, Tokish JM, Hattrup SJ. Clinical efficacy of liposomal bupivacaine: a systematic review of prospective, randomized controlled trials in orthopaedic surgery. *JBJS Rev.* 2019 Jul;7(7):e8.
2. Addeo A, Weiss GJ, Gyawali B. Association of industry and academic sponsorship with negative phase 3 oncology trials and reported outcomes on participant survival: A pooled analysis. *JAMA Netw Open.* 2019 May 3;2(5):e193684.
3. Ahmer S, Arya P, Anderson D, Faruqui R. Conflict of interest in psychiatry. *Psychiatric Bulletin.* 2005 Aug;29(8):302-4.
4. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. *BMJ.* 2017 Jan 17;356:i6770.
5. Alasbali T, Smith M, Geffen N, Trope GE, Flanagan JG, Jin Y, et al. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins. *Am J Ophthalmol.* 2009 Jan;147(1):33-38.e2.

6. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? *JAMA*. 2003 Aug 20;290(7):921–8.
7. Avni T, Shiber-Ofer S, Leibovici L, Paul M. Assessment of bias in outcomes reported in trials on pneumonia: a systematic review. *Eur J Clin Microbiol Infect Dis*. 2014 Jun;33(6):969–74.
8. Azad TD, Feng AY, Mehta S, Bak AB, Johnson E, Mittal V, et al. Randomized controlled trials in functional neurosurgery—association of device approval status and trial quality. *Neuromodulation: Technology at the Neural Interface*. 2020;23(4):496–501.
9. Azharuddin M, Adil M, Khan RA, Ghosh P, Kapur P, Sharma M. Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal. *Osteoporosis and Sarcopenia*. 2020 Jun 1;6(2):39–52.
10. Barden J, Derry S, McQuay HJ, Moore AR. Bias from industry trial funding? A framework, a suggested approach, and a negative result. *Pain*. 2006 Apr;121(3):207–18.
11. Bariani GM, de Celis Ferrari ACR, Hoff PM, Krzyzanowska MK, Riechelmann RP. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. *J Clin Oncol*. 2013 Jun 20;31(18):2289–95.
12. Bartels RHMA, Delye H, Boogaarts J. Financial disclosures of authors involved in spine research: an underestimated source of bias. *Eur Spine J*. 2012 Jul;21(7):1229–33.
13. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. *PLoS Med*. 2007 Jun;4(6):e184.
14. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. *CMAJ*. 2004 Feb 17;170(4):477–80.
15. Bighelli I, Leucht C, Huhn M, Reitmeir C, Schwermann F, Wallis S, et al. Are randomized controlled trials on pharmacotherapy and psychotherapy for positive symptoms of schizophrenia comparable? a systematic review of patient and study characteristics. *Schizophr Bull*. 2020 Apr 10;46(3):496–504.
16. Bond K, Spooner C, Tjosvold L, Lemièrè C, Rowe BH. The nature and influence of pharmaceutical industry involvement in asthma trials. *Can Respir J*. 2012;19(4):267–71.
17. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. *J Clin Oncol*. 2008 Nov 20;26(33):5458–64.
18. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. *Ann Intern Med*. 2010 Aug 3;153(3):158–66.
19. Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah R, et al. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. *Clin Gastroenterol Hepatol*. 2006 Dec;4(12):1445–51.
20. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. *Ann Pharmacother*. 2004 Apr;38(4):579–85.
21. Budhiraja P, Kaplan B, Kalot M, Alayli AE, Dimassi A, Chakkeria HA, et al. Current state of evidence on kidney transplantation: how fragile are the results? *Transplantation*. 2022 Feb 1;106(2):248–56.
22. Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, et al. Use of expansion cohorts in phase I trials and probability of success in phase II for 381 anticancer drugs. *Clin Cancer Res*. 2017 Aug 1;23(15):4020–6.
23. Catillon M. Trends and predictors of biomedical research quality, 1990–2015: A meta-research study. *BMJ Open*. 2019 Sep 1;9:e030342.
24. Chang MJ, Qiu Y, Lipner SR. Race reporting and representation in onychomycosis clinical trials: A systematic review. *Mycoses*. 2021 Aug;64(8):954–66.
25. Chard JA, Tallon D, Dieppe PA. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. *Ann Rheum Dis*. 2000 Jun;59(6):414–8.
26. Chen Y-P, Liu X, Lv J-W, Li W-F, Zhang Y, Guo Y, et al. Publication status of contemporary oncology randomised controlled trials worldwide. *Eur J Cancer*. 2016 Oct;66:17–25.

27. Cherla DV, Viso CP, Holihan JL, Bernardi K, Moses ML, Mueck KM, et al. The effect of financial conflict of interest, disclosure status, and relevance on medical research from the united states. *J Gen Intern Med.* 2019 Mar;34(3):429–34.
28. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. *Ann Intern Med.* 1996 Mar 1;124(5):485–9.
29. Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. *BMC Cancer.* 2002 Sep 24;2:23.
30. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. *BMC Health Serv Res.* 2002 Sep 4;2(1):18.
31. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. *J Sex Med.* 2014 Jun;11(6):1577–92.
32. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2014 Oct;13(10):1327–51.
33. Cristea IA, Gentili C, Pietrini P, Cuijpers P. Is investigator background related to outcome in head to head trials of psychotherapy and pharmacotherapy for adult depression? A systematic review and meta-analysis. *PLoS One.* 2017;12(2):e0171654.
34. Crocetti MT, Amin DD, Scherer R. Assessment of risk of bias among pediatric randomized controlled trials. *Pediatrics.* 2010 Aug;126(2):298–305.
35. Vrljićak Davidović N, Komić L, Mešin I, Kotarac M, Okmažić D, Franić T. Registry versus publication: discrepancy of primary outcomes and possible outcome reporting bias in child and adolescent mental health. *Eur Child Adolesc Psychiatry.* 2021 Jan 18;
36. Davidson RA. Source of funding and outcome of clinical trials. *J Gen Intern Med.* 1986 Jun;1(3):155–8.
37. Davis JM, Chen N, Glick ID. Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. *Neuropsychopharmacology.* 2008 Apr;33(5):971–5.
38. de Souza Gutierrez B, Aguiar PN, Dourado BB, Alves AL, Matsas S, Simões AR, et al. Evidence strength of pharmaceutical industry-funded clinical trials in metastatic nscl: a comparison with other sources of funding. *J Thorac Oncol.* 2020 Jul;15(7):1170–6.
39. DeFrance MJ, Yayac MF, Courtney PM, Squire MW. The impact of author financial conflicts on robotic-assisted joint arthroplasty research. *J Arthroplasty.* 2021 Apr;36(4):1462–9.
40. DeGeorge BR, Holland MC, Drake DB. The impact of conflict of interest in abdominal wall reconstruction with acellular dermal matrix. *Ann Plast Surg.* 2015 Feb;74(2):242–7.
41. Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? *Ann Oncol.* 2017 Jan 1;28(1):157–62.
42. Falk Delgado A, Falk Delgado A. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis. *Trials.* 2017 Mar 14;18(1):125.
43. Falk Delgado A, Falk Delgado A. Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis. *Sci Rep.* 2017 Aug 23;7:9206.
44. DePasse JM, Park S, Eltorai AEM, Daniels AH. Factors predicting publication of spinal cord injury trials registered on www.ClinicalTrials.gov. *J Back Musculoskelet Rehabil.* 2018 Feb 6;31(1):45–8.
45. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. *Lancet.* 2020 Feb 1;395(10221):361–9.
46. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. *Lancet.* 2000 Aug 19;356(9230):635–8.
47. Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. *PLoS One.* 2013;8(3):e58711.
48. Etter J-F, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. *Addiction.* 2007 May;102(5):815–22.

49. Finucane TE, Boulton CE. Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. *Am J Med.* 2004 Dec 1;117(11):842–5.
50. Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. *J Clin Epidemiol.* 2015 Jul;68(7):811–20.
51. Fraguas D, Díaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: a meta-regression analysis. *Schizophr Bull.* 2019 Jan 1;45(1):57–68.
52. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. *Br J Psychiatry.* 2000 Oct;177:292–302.
53. Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible translation of stem cell research: an assessment of clinical trial registration and publications. *Stem Cell Reports.* 2017 May 9;8(5):1190–201.
54. Gabler NB, Duan N, Ranases E, Suttner L, Ciarametaro M, Cooney E, et al. No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals. *Trials.* 2016 Jul 16;17(1):320.
55. Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. *J Natl Cancer Inst.* 2012 Apr 18;104(8):590–8.
56. Gao Y, Ge L, Ma X, Shen X, Liu M, Tian J. Improvement needed in the network geometry and inconsistency of Cochrane network meta-analyses: a cross-sectional survey. *J Clin Epidemiol.* 2019 Sep;113:214–27.
57. Gartlehner G, Morgan L, Thieda P, Fleg A. The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. *J Clin Epidemiol.* 2010 Feb;63(2):117–25.
58. Gaudino M, Hameed I, Rahouma M, Khan FM, Tam DY, Biondi-Zoccai G, et al. Characteristics of contemporary randomized clinical trials and their association with the trial funding source in invasive cardiovascular interventions. *JAMA Intern Med.* 2020 Jul 1;180(7):993–1001.
59. González-González JG, Dorsey-Treviño EG, Alvarez-Villalobos N, Barrera-Flores FJ, Díaz González-Colmenero A, Quintanilla-Sánchez C, et al. Trustworthiness of randomized trials in endocrinology-A systematic survey. *PLoS One.* 2019;14(2):e0212360.
60. Grey P, Grey A, Bolland MJ. Outcomes, interventions and funding in randomised research published in high-impact journals. *Trials.* 2018 Oct 29;19(1):592.
61. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. *JAMA Netw Open.* 2019 Aug 2;2(8):e199570.
62. Hajibandeh S, Hajibandeh S, Antoniou SA, Antoniou GA, Torella F. Industry sponsorship and positive outcome in vascular and endovascular randomised trials. *Vasa.* 2017 Jan;46(1):67–8.
63. Halpern SD, Barton TD, Gross R, Hennessy S, Berlin JA, Strom BL. Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. *Pharmacoepidemiol Drug Saf.* 2005 Mar;14(3):155–61.
64. Hanna E, Rémuzat C, Auquier P, Toumi M. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. *J Mark Access Health Policy.* 2016;4.
65. Hashemipour MA, Pourmonajemzadeh S, Zoghitavana S, Navabi N. Relationship between declarations of conflict of interests and reporting positive outcomes in Iranian dental journals. *Sci Eng Ethics.* 2019 Aug;25(4):1057–67.
66. Hengartner MP, Amendola S, Kaminski JA, Kindler S, Bschor T, Plöderl M. Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. *J Epidemiol Community Health.* 2021 Mar 8;jech-2020-214611.
67. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry.* 2006 Feb;163(2):185–94.

68. Janiaud P, Cristea I-A, Ioannidis JPA. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview. *Intensive Care Med*. 2018 Oct;44(10):1613–27.
69. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. *BMJ*. 2009 Feb 12;338:b354.
70. Jellison S, Roberts W, Bowers A, Combs T, Beaman J, Wayant C, et al. Evaluation of spin in abstracts of papers in psychiatry and psychology journals. *BMJ Evid Based Med*. 2019 Aug 5;178–81.
71. Jinapriya D, Anraku A, Alasbali T, Trope GE, Buys YM. Evaluation of investigator bias in industry-funded clinical trials of latanoprost. *Can J Ophthalmol*. 2011 Dec;46(6):531–6.
72. Johnson AL, Fladie I, Anderson JM, Lewis DM, Mons BR, Vassar M. Rates of discontinuation and nonpublication of head and neck cancer randomized clinical trials. *JAMA Otolaryngol Head Neck Surg*. 2020 Feb 1;146(2):176–82.
73. Jones R, Younie S, Macallister A, Thornton J. A comparison of the scientific quality of publicly and privately funded randomized controlled drug trials. *J Eval Clin Pract*. 2010 Dec;16(6):1322–5.
74. Kakkar AK, Padhy BM, Sarangi SC, Gupta YK. Methodological characteristics of clinical trials: impact of mandatory trial registration. *J Pharm Pharm Sci*. 2019;22(1):131–41.
75. Kapelios CJ, Naci H, Vardas PE, Mossialos E. Study design, result posting and publication of late-stage cardiovascular trials. *Eur Heart J Qual Care Clin Outcomes*. 2020 Oct 24;qcaa080.
76. Kelly R, Cohen L, Semple R, Bialer P, Lau A, Bodenheimer A, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. *Psychological medicine*. 2006 Dec 1;36:1647–56.
77. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. *BMJ*. 2001 Jul 21;323(7305):131–4.
78. Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. *Arthritis Rheum*. 2012 Jul;64(7):2059–67.
79. Killin LOJ, Russ TC, Starr JM, Abrahams S, Della Sala S. The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis. *BMJ Open*. 2014 Apr 7;4(4):e004083.
80. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. *BMJ*. 2002 Aug 3;325(7358):249.
81. Lee KC, Wu BW, Chuang S-K. Which factors affect the completion and publication of dental implant trials? *J Oral Maxillofac Surg*. 2020 Oct;78(10):1726–35.
82. Lee Y-K, Chung CY, Koo K-H, Lee KM, Ji H-M, Park MS. Conflict of interest in the assessment of thromboprophylaxis after total joint arthroplasty: a systematic review. *J Bone Joint Surg Am*. 2012 Jan 4;94(1):27–33.
83. Leite ETT, Moraes FY, Marta GN, Taunk NK, Vieira MTL, Hanna SA, et al. Trial sponsorship and self-reported conflicts of interest in breast cancer radiation therapy: An analysis of prospective clinical trials. *Breast*. 2017 Jun;33:29–33.
84. Leucht S, Chaimani A, Mavridis D, Leucht C, Huhn M, Helfer B, et al. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. *Neuropsychopharmacology*. 2019 Oct;44(11):1955–66.
85. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry*. 2017 Oct 1;174(10):927–42.
86. Liang F, Zhu J, Mo M, Zhou CM, Jia HX, Xie L, et al. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication. *Ann Oncol*. 2018 Oct 1;29(10):2129–34.
87. Liss H. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. *Isr Med Assoc J*. 2006 Jul;8(7):451–4.

88. Liu X, Zhang Y, Tang L-L, Le QT, Chua MLK, Wee JTS, et al. Characteristics of radiotherapy trials compared with other oncological clinical trials in the past 10 years. *JAMA Oncol*. 2018 Aug 1;4(8):1073–9.
89. Lubowitz JH, Appleby D, Centeno JM, Woolf SK, Reid JB. The relationship between the outcome of studies of autologous chondrocyte implantation and the presence of commercial funding. *Am J Sports Med*. 2007 Nov;35(11):1809–16.
90. Lynch J, Cunningham M, Warne W, Schaad D, Wolf F, Leopold S. Commercially funded and united states-based research is more likely to be published; good-quality studies with negative outcomes are not. *The Journal of bone and joint surgery American volume*. 2007 Jun 1;89:1010–8.
91. Ma D, Zhang Z, Zhang X, Li L. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis. *Curr Med Res Opin*. 2014 Jun;30(6):971–95.
92. Magnani CJ, Steinberg JR, Harmange CI, Zhang X, Driscoll C, Bell A, et al. Clinical trial outcomes in urology: assessing early discontinuation, results reporting and publication in clinicaltrials.gov registrations 2007-2019. *J Urol*. 2021 Apr;205(4):1159–68.
93. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. *Ann Oncol*. 2016 Jan;27(1):192–8.
94. Malek E, Saygin C, Ye R, Covut F, Kim B-G, Welge J, et al. Predicting successful phase advancement and regulatory approval in multiple myeloma from phase I overall response rates. *JCO Clin Cancer Inform*. 2017 Nov;1:1–14.
95. Mian MK, Sreedharan S, Limaye NS, Hogan C, Darvall JN. Research trends in anticoagulation therapy over the last 25 years. *Semin Thromb Hemost*. 2020 Nov;46(8):919–31.
96. Mitchell JM, Patterson JA. The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov. *J Manag Care Spec Pharm*. 2020 Apr;26(4):386–93.
97. Momeni A, Becker A, Bannasch H, Antes G, Blümle A, Stark GB. Association between research sponsorship and study outcome in plastic surgery literature. *Ann Plast Surg*. 2009 Dec;63(6):661–4.
98. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. *Br J Psychiatry*. 2003 Aug;183:161–6.
99. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. *Control Clin Trials*. 2004 Dec;25(6):598–612.
100. Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, Souhami L, et al. Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. *J Neurooncol*. 2018 Feb;136(3):585–93.
101. Mossman SA, Mills JA, Walkup JT, Strawn JR. The impact of failed antidepressant trials on outcomes in children and adolescents with anxiety and depression: a systematic review and meta-analysis. *J Child Adolesc Psychopharmacol*. 2021 May;31(4):259–67.
102. Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. *BMJ*. 2014 Oct 3;349:g5741.
103. Ng T, Mazzarello S, Wang Z, Hutton B, Dranitsaris G, Vandermeer L, et al. Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. *Breast Cancer Res Treat*. 2016 Jan;155(2):337–44.
104. Nieto A, Mazon A, Pamies R, Linana JJ, Lanuza A, Jiménez FO, et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. *Arch Intern Med*. 2007 Oct 22;167(19):2047–53.
105. Nithianandan H, Kuriyan AE, Venincasa MJ, Sridhar J. Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review. *Clin Ophthalmol*. 2020;14:2383–95.
106. Oduyayo A, Emdin CA, Hsiao AJ, Shakir M, Copsey B, Dutton S, et al. Association between trial registration and positive study findings: cross sectional study (Epidemiological Study of Randomized Trials-ESORT). *BMJ*. 2017 Mar 14;356:j917.

107. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. *JAMA Oncol.* 2021 May 1;7(5):728–34.
108. Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, et al. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. *Eur J Cancer.* 2020 Sep;136:176–85.
109. Pengel LHM, Barcena L, Morris PJ. The quality of reporting of randomized controlled trials in solid organ transplantation. *Transpl Int.* 2009 Apr;22(4):377–84.
110. Pepper DJ, Sun J, Rhee C, Welsh J, Powers JH, Danner RL, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults. *Chest.* 2019 Jun;155(6):1109–18.
111. Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. *Cancer.* 2007 Apr 1;109(7):1239–46.
112. Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship conflicts of interest in dermatology research. *J Am Acad Dermatol.* 2005 Jun;52(6):967–71.
113. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *Am J Psychiatry.* 2005 Oct;162(10):1957–60.
114. Popelut A, Valet F, Fromentin O, Thomas A, Bouchard P. Relationship between sponsorship and failure rate of dental implants: a systematic approach. *PLoS One.* 2010 Apr 21;5(4):e10274.
115. Pouwels XGLV, Ramaekers BLT, Joore MA. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. *Breast Cancer Res Treat.* 2017 Oct;165(3):485–98.
116. Prakash VS, Mansukhani NA, Helenowski IB, Woodruff TK, Kibbe MR. Sex bias in interventional clinical trials. *J Womens Health (Larchmt).* 2018 Nov;27(11):1342–8.
117. Price-Haywood EG, Harden-Barrios J, Carr C, Reddy L, Bazzano LA, van Driel ML. Patient-reported outcomes in stroke clinical trials 2002-2016: a systematic review. *Qual Life Res.* 2019 May;28(5):1119–28.
118. Printz JO, Lee JJ, Knesek M, Urquhart AG. Conflict of interest in the assessment of hyaluronic acid injections for osteoarthritis of the knee: an updated systematic review. *J Arthroplasty.* 2013 Sep;28(8 Suppl):30-33.e1.
119. Probst P, Knebel P, Grummich K, Tenckhoff S, Ulrich A, Büchler MW, et al. Industry bias in randomized controlled trials in general and abdominal surgery: an empirical study. *Ann Surg.* 2016 Jul;264(1):87–92.
120. Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev.* 2016 Feb 4;2:CD009996.
121. Putman MS, Harrison Ragle A, Ruderman EM. The quality of randomized controlled trials in high-impact rheumatology journals, 1998-2018. *J Rheumatol.* 2020 Sep 1;47(9):1446–9.
122. Raman S, Moraes FY, Mendez LC, Taunk NK, Suh JH, Souhami L, et al. The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. *J Neurooncol.* 2018 Aug;139(1):195–203.
123. Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. *Trials.* 2009 Dec 16;10:116.
124. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. *PLoS One.* 2009 Jun 8;4(6):e5826.
125. Reda S, Elhennawy K, Meyer-Lückel H, Paris S, Schwendicke F. Industry sponsorship in trials on fluoride varnish or gels for caries prevention. *Community Dent Oral Epidemiol.* 2017 Aug;45(4):289–95.
126. Rees CA, Pica N, Monuteaux MC, Bourgeois FT. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis. *PLoS Med.* 2019 Nov 21;16(11):e1002966.
127. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. *JAMA.* 2006 May 17;295(19):2270–4.

128. Rios LP, Oduyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. *J Clin Endocrinol Metab.* 2008 Oct;93(10):3810–6.
129. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Arch Intern Med.* 1994 Jan 24;154(2):157–63.
130. Roddick AJ, Chan FTS, Stefaniak JD, Zheng SL. Discontinuation and non-publication of clinical trials in cardiovascular medicine. *Int J Cardiol.* 2017 Oct 1;244:309–15.
131. Roper N, Zhang N, Korenstein D. Industry collaboration and randomized clinical trial design and outcomes. *JAMA Intern Med.* 2014 Oct;174(10):1695–6.
132. Rösner S, Hackl-Herrwerth A, Leucht S, Leherth P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. *Cochrane Database Syst Rev.* 2010 Sep 8;(9):CD004332.
133. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. *Cochrane Database Syst Rev.* 2010 Dec 8;(12):CD001867.
134. Saa C, Bunout D, Hirsch S. Industry funding effect on positive results of probiotic use in the management of acute diarrhea: a systematized review. *Eur J Gastroenterol Hepatol.* 2019 Mar;31(3):289–302.
135. Saleh RR, Meti N, Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, et al. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. *Cancer Med.* 2020 Nov;9(21):7888–95.
136. Sendyk DI, Rovai ES, Souza NV, Deboni MCZ, Pannuti CM. Selective outcome reporting in randomized clinical trials of dental implants. *J Clin Periodontol.* 2019 Jul;46(7):758–65.
137. Shepard S, Wise A, Johnson BS, Sajjadi NB, Hartwell M, Vassar M. Are randomized controlled trials in urology being conducted with justification? *J Osteopath Med.* 2021 May 21;121(8):665–71.
138. Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, et al. Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis. *Neurology.* 2017 Jun 6;88(23):2216–24.
139. Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. *Cochrane Database Syst Rev.* 2019 Jun 28;6:CD004039.
140. Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lancôt KL, Grysman NH. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials. *J Clin Psychiatry.* 2012 Feb;73(2):e277–287.
141. Son C, Tavakoli S, Bartanusz V. No publication bias in industry funded clinical trials of degenerative diseases of the spine. *J Clin Neurosci.* 2016 Mar;25:58–61.
142. Spanemberg L, Massuda R, Lovato L, Paim L, Vares EA, Sica da Rocha N, et al. Pharmacological treatment of bipolar depression: qualitative systematic review of double-blind randomized clinical trials. *Psychiatr Q.* 2012 Jun;83(2):161–75.
143. Sriganesh K, Bharadwaj S, Wang M, Abbade LPF, Jin Y, Philip M, et al. Quality of abstracts of randomized control trials in five top pain journals: A systematic survey. *Contemp Clin Trials Commun.* 2017 Sep;7:64–8.
144. Stefaniak JD, Lam TCH, Sim NE, Al-Shahi Salman R, Breen DP. Discontinuation and non-publication of neurodegenerative disease trials: a cross-sectional analysis. *Eur J Neurol.* 2017 Aug;24(8):1071–6.
145. Steffens ANV, Langerhuizen DWG, Doornberg JN, Ring D, Janssen SJ. Emotional tones in scientific writing: comparison of commercially funded studies and non-commercially funded orthopedic studies. *Acta Orthop.* 2021 Apr;92(2):240–3.
146. Sung KH, Chung CY, Lee KM, Lee Y-K, Lee SY, Lee J, et al. Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review. *J Pediatr Orthop.* 2013 Aug;33(5):494–500.
147. Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, et al. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. *Oncotarget.* 2018 Mar 13;9(19):15061–7.

148. Trinquart L, Dunn AG, Bourgeois FT. Registration of published randomized trials: a systematic review and meta-analysis. *BMC Med.* 2018 Oct 16;16(1):173.
149. Tulikangas PK, Ayers A, O'Sullivan DM. A meta-analysis comparing trials of antimuscarinic medications funded by industry or not. *BJU Int.* 2006 Aug;98(2):377–80.
150. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. *Br J Psychiatry.* 2007 Jul;191:82–3.
151. Urrutia G, Ballesteros M, Djulbegovic B, Gich I, Roqué M, Bonfill X. Cancer randomized trials showed that dissemination bias is still a problem to be solved. *J Clin Epidemiol.* 2016 Sep;77:84–90.
152. van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, et al. Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study. *J Clin Epidemiol.* 2017 Sep;89:199–208.
153. van Heteren JAA, van Beurden I, Peters JPM, Smit AL, Stegeman I. Trial registration, publication rate and characteristics in the research field of otology: A cross-sectional study. *PLoS One.* 2019;14(7):e0219458.
154. van Lent M, Overbeke J, Out HJ. Role of editorial and peer review processes in publication bias: analysis of drug trials submitted to eight medical journals. *PLoS One.* 2014;9(8):e104846.
155. Venincasa MJ, Kuriyan AE, Sridhar J. Effect of funding source on reporting bias in studies of intravitreal anti-vascular endothelial growth factor therapy for retinal vein occlusion. *Acta Ophthalmol.* 2019 Mar;97(2):e296–302.
156. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? *Arthritis Rheum.* 2007 Jul;56(7):2267–77.
157. Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. *Am J Psychiatry.* 2017 May 1;174(5):430–7.
158. Walter SD, Han H, Guyatt GH, Bassler D, Bhatnagar N, Gloy V, et al. A systematic survey of randomised trials that stopped early for reasons of futility. *BMC Med Res Methodol.* 2020 Jan 16;20(1):10.
159. Waqas A, Baig AA, Khalid MA, Aedma KK, Naveed S. Conflicts of interest and outcomes of clinical trials of antidepressants: an 18-year retrospective study. *J Psychiatr Res.* 2019 Sep;116:83–7.
160. Welsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, et al. Age of data at the time of publication of contemporary clinical trials. *JAMA Netw Open.* 2018 Aug 3;1(4):e181065.
161. Wise A, Mannem D, Anderson JM, Weaver M, Hartwell M, Vassar M. Do author conflicts of interest and industry sponsorship influence outcomes of systematic reviews and meta-analyses regarding glaucoma interventions? a cross-sectional analysis. *J Glaucoma.* 2021 Apr 1;30(4):293–9.
162. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics.* 2019 Apr 1;20(2):273–86.
163. Wortzel JR, Turner BE, Weeks BT, Fragassi C, Ramos V, Truong T, et al. Trends in mental health clinical research: Characterizing the ClinicalTrials.gov registry from 2007-2018. *PLoS One.* 2020;15(6):e0233996.
164. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med.* 2013 Apr 18;11:108.
165. Yilmaz T, Jutten RJ, Santos CY, Hernandez KA, Snyder PJ. Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease. *Alzheimers Dement (N Y).* 2018;4:161–4.
166. Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. *Cochrane Database Syst Rev.* 2016 Apr 23;4:CD003719.
167. Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *Int J Neuropsychopharmacol.* 2013 Jul;16(6):1205–18.